Low-Dose Naltrexone Cost in Massachusetts (2026): Prices, Insurance, and Savings

The direct answer

Low-dose naltrexone in Massachusetts is not a manufactured, FDA-priced product. It is a compounded preparation made to order by a state-licensed 503A pharmacy from bulk naltrexone powder, because no manufacturer sells a pre-made 1.5-4.5 mg capsule. That single fact explains almost everything about its cost and coverage: prices are set by individual pharmacies rather than a national formulary, insurers that build their benefit around FDA-approved dosage forms often exclude compounded products by category, and the number you are quoted this month can differ from the number quoted six months from now. National reporting on compounded LDN commonly cites a range around $30 to $65 for a 30-day supply, but no Massachusetts-specific price survey is cited in the source material for this page, so treat any single number as a starting point for phone calls, not a guarantee.

What LDN is, and what it is not

Naltrexone is an opioid receptor antagonist. The FDA-approved oral tablet, 50 mg once daily, is indicated for alcohol use disorder and for blocking the effects of opioids in opioid use disorder (FDA label, NDA 018932). An extended-release injectable formulation (marketed as Vivitrol) is also FDA-approved for these indications. Low-dose naltrexone uses the same active ingredient at roughly one-tenth the approved dose, typically 1.5-4.5 mg, for conditions such as fibromyalgia or Crohn's disease. This use is off-label: the FDA has not evaluated naltrexone at these doses for these indications, and the low-dose capsule itself exists only because a compounding pharmacy makes it.

Compounding of a drug not commercially available in the needed strength is a recognized pathway under section 503A of the Federal Food, Drug, and Cosmetic Act, described on the FDA's compounding laws and policies page. Massachusetts licenses and inspects 503A pharmacies through its Board of Registration in Pharmacy, and licensed compounders must meet USP non-sterile compounding standards. Before filling any compounded prescription, confirm the pharmacy's Massachusetts license is current; this is a real safety check, not a formality, given past contamination incidents at compounding facilities in other states.

What the cost actually depends on

Because there is no manufacturer list price, LDN's cost is a function of three things: the compounding pharmacy's ingredient and labor costs, the quantity you order, and whether a discount or subscription program applies.

• Pharmacy choice. Prices for a 30-day supply of 4.5 mg capsules commonly cited in the compounding industry range from roughly $28 to $65. Call at least two or three Massachusetts 503A pharmacies for current quotes; prices are not standardized and change.
• Quantity. A 90-day fill is often discounted per unit compared with three separate 30-day fills, though the exact discount varies by pharmacy.
• Formulation. Standard oral capsules are usually the cheapest option. Sublingual drops or topical creams, when available, tend to cost more.
• Insurance and discount programs. These are the least stable part of the price and the part most likely to be wrong if you rely on a general article instead of your own plan documents (see below).

Does Massachusetts Medicaid cover LDN?

MassHealth, like most state Medicaid programs, can require prior authorization for off-label uses of a drug, and coverage decisions for a compounded product are generally handled case by case. What is established: prior authorization is the mechanism by which an off-label, compounded drug like LDN would plausibly be covered. What is not established from the source material behind this page: the exact approval timeline, the specific first-line therapies MassHealth requires you to have tried, and the exact copay tier. Earlier drafts of this kind of article often state precise numbers (specific business-day turnaround times, specific copay amounts) without a citable MassHealth policy document behind them. Treat any such figure as unverified until you or your prescriber confirm it directly with MassHealth or your MassHealth managed care plan, since these criteria change and are not something a general medical information page can state reliably.

A separate practical point that is not insurance-dependent: not every compounding pharmacy in Massachusetts participates in the MassHealth network. Confirm network participation before assuming a MassHealth-covered path is available at a specific pharmacy.

Commercial insurance: the general pattern, and its limits

The broad pattern across commercial insurance nationally, including in Massachusetts, is that formularies are built around FDA-approved dosage forms. Generic naltrexone 50 mg tablets, used for alcohol or opioid use disorder, are commonly covered because they are an approved product with a National Drug Code. Compounded preparations, including LDN capsules, are frequently excluded from commercial formularies as a category regardless of the active ingredient, because there is no standardized product for the plan to price and authorize. This is a structural feature of how compounding benefits are (or are not) written into most commercial plans, not a clinical judgment about LDN itself.

Naming specific Massachusetts insurers and asserting their exact compounding policy is not something this page can support without a current, plan-specific source, and those policies change. If you have commercial insurance, ask your plan directly whether compounded medications are covered under any circumstance, whether a formulary exception process exists, and whether your specific employer plan (if self-funded) has added a compounding benefit that a standard plan document would not show.

One thing worth flagging clinically rather than financially: some patients try to approximate a low dose by splitting or dissolving a covered 50 mg tablet instead of paying for a compounded capsule. This is not a precise or reliably dosed approach, since the tablet's excipients and release profile are designed for the full 50 mg dose, and manipulating it can affect how much drug is actually delivered. A compounded capsule made specifically at the intended low dose is the more predictable option even though it usually costs more out of pocket.

Telehealth prescribing

Massachusetts generally permits telehealth prescribing following the broader expansion of telehealth parity rules after the COVID-19 emergency. Several national telehealth platforms offer LDN consultations to Massachusetts residents, sometimes bundling the visit fee with a compounded medication fill. Specific visit fees and bundled-price figures change frequently and are set by the platform, not by state policy, so confirm current pricing directly with any telehealth service before committing, and confirm that the prescribing clinician is licensed in Massachusetts.

The evidence behind LDN's use

The clinical evidence for LDN in conditions like fibromyalgia, Crohn's disease, and multiple sclerosis consists of small trials, pilot studies, and open-label or retrospective work, not a completed large-scale randomized controlled trial for any indication as of this writing. Because the specific paper identifiers commonly cited for this literature could not be independently verified for this draft, the studies are described here in general terms rather than with exact effect sizes:

• A small placebo-controlled crossover trial in fibromyalgia reported reduced pain measures with LDN 4.5 mg compared with placebo.
• A separate small trial in Crohn's disease reported improved clinical response and remission rates with LDN compared with placebo.
• A small trial in multiple sclerosis found LDN well tolerated but did not find a statistically significant improvement in quality-of-life scores, and the study was considered underpowered.

If a specific percentage or p-value is important to your decision, ask your prescriber to pull the primary paper rather than relying on a secondary summary, including this one. The NIH's ClinicalTrials.gov database lists ongoing LDN trials in several conditions and is a reasonable place to check for more recent, registered research.

Patient-reported data from advocacy organizations, such as the LDN Research Trust, a UK-based nonprofit that surveys LDN users, can be informative about real-world experience but is not clinical trial evidence and should be weighed accordingly.

What is established, what is plausible, and what is not established

Established: Naltrexone 50 mg is FDA-approved for alcohol and opioid use disorder. Low-dose naltrexone is a compounded, off-label use of the same molecule. Compounding under 503A rules is a legal, FDA-recognized pathway when a needed strength is not commercially available. Naltrexone can precipitate acute withdrawal in people currently using opioids, and the FDA label for the 50 mg tablet carries a hepatotoxicity warning at higher doses.

Plausible but not proven at scale: LDN may reduce symptoms in fibromyalgia, Crohn's disease, and some other chronic inflammatory or pain conditions, based on small trials. A proposed mechanism involves transient opioid receptor blockade and modulation of glial cell signaling, but this remains a hypothesis under active study rather than a settled mechanism.

Not established from the source material for this page: exact Massachusetts price figures across pharmacies, specific MassHealth prior-authorization timelines and copay amounts, and insurer-by-insurer commercial coverage rules in Massachusetts. These are exactly the facts that change fastest and that a general article cannot certify on your behalf.

When LDN is not appropriate, and when to seek urgent care

LDN is contraindicated in anyone currently taking an opioid medication, including opioid pain relievers, opioid-containing cough suppressants, and buprenorphine used for opioid use disorder, because naltrexone blocks opioid receptors and can trigger acute withdrawal. Prescribers generally require an opioid-free interval, commonly cited as at least 7-10 days and sometimes longer, before starting LDN; the exact interval should be set by your prescriber based on which opioid you used and how recently. LDN is not recommended in pregnancy due to insufficient safety data, and caution applies in significant liver impairment given hepatic metabolism of the drug. Baseline and follow-up liver function testing is a reasonable and commonly used precaution, consistent with the general monitoring philosophy in the naltrexone label, even though hepatotoxicity has not been the dominant safety signal at low doses in the available small studies.

Seek urgent medical care if you experience signs of opioid withdrawal after starting naltrexone (agitation, sweating, vomiting, diarrhea, rapid heart rate) or signs of liver injury (yellowing of skin or eyes, dark urine, severe abdominal pain, unusual fatigue).

Verification checklist: what you can trust as stable versus what you must confirm before paying

Use this before you commit to a pharmacy, a telehealth platform, or a prior-authorization process. The left column is unlikely to change month to month. The right column is exactly the kind of fact that a general article, including this one, cannot certify for you on any given day.

If a number in this article or anywhere else does not match what the pharmacy or plan tells you today, trust the pharmacy or plan and treat the article as background context rather than a current price sheet.

Where to get help

If you qualify for MassHealth, ask your prescriber to submit prior authorization documentation and confirm your specific plan's current cost-sharing before you fill. If you are uninsured or your commercial plan excludes compounding, calling several Massachusetts 503A pharmacies for a same-day quote, and asking about 90-day pricing, is the most direct way to find your actual out-of-pocket cost. The Massachusetts Board of Registration in Pharmacy's public license lookup can confirm a compounding pharmacy's current standing before you send a prescription there.